Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Raphael Pharmaceutical Inc. (RAPH : OTC)

• Company Description    Rafael Pharmaceuticals Inc. is focused on the development of rare cancer therapeutics. The company's lead compound includes CPI-613(R) is designed to target the mitochondria of cancer cells in order to disrupt their energy production, cutting off the fuel for disease growth. Rafael Pharmaceuticals Inc. is based in Cranbury, NJ. Number of Employees:

• Price / Volume Information    Yesterday's Closing Price: $0.75 Daily Weekly Monthly 20 Day Moving Average: 7 shares Shares Outstanding: 19.63 (millions) Market Capitalization: $14.72 (millions) Beta: 2.07 52 Week High: $1.00 52 Week Low: $0.15 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 240.91% 228.14% 12 Week -25.00% -36.92% Year To Date 188.46% 170.14%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 4 Lui Paster - Tel Aviv- Jaffa,L3 6803605 ISR ph: 972-52-775-5072 fax: - None http://www.raphaelpharmaceutical.com

• General Corporate Information    Officers Shlomo Pilo - Chief Executive Officer and Director Ajay Kumar Dhadha - Chairman and Director Guy Ofir - Chief Financial Officer and Director Igal Louria Hayon - Chief Technology Officer and Director Yehuda Eliya - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 27785B208 SIC: 2833 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/11/25 Share - Related Items Shares Outstanding: 19.63 Most Recent Split Date: (:1) Beta: 2.07 Market Capitalization: $14.72 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/11/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 33.33% vs. Previous Quarter: 0.00% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - - 12/31/24 - - ROA 06/30/25 - - 03/31/25 - -1,954.52 12/31/24 - -1,086.94 Current Ratio 06/30/25 - - 03/31/25 - 0.11 12/31/24 - 0.03 Quick Ratio 06/30/25 - - 03/31/25 - 0.11 12/31/24 - 0.03 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - -0.04 12/31/24 - -0.04 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Capital 06/30/25 - - 03/31/25 - - 12/31/24 - -

Powered by Zacks Investment Research ©